Common stock, par value $0.01 per share
- Symbol
- CERT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01 · 8-K
Certara, Inc.
CERTNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 4, 2026, Certara, Inc. (the “Company”) hosted its second quarter 2026 earnings conference call and posted on its website its second quarter 2026 earnings presentation.…
Company context
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Current securities
Recent company filings
- 10-Q filingAug 4, 2026
- Results of Operations and Financial ConditionAug 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 17, 2026
- Submission of Matters to a Vote of Security HoldersMay 15, 2026
Registered securities in this filing
Certara, Inc. · 8-K · Filed 2026-08-07
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01
Regulation FD Disclosure.
On August 4, 2026, Certara, Inc. (the “Company”) hosted
its second quarter 2026 earnings conference call and posted on its website its second quarter 2026 earnings presentation. On the earnings
conference call, there was a misstatement in the spoken reference to the 2025 adjusted EBITDA generated by the Company’s recently
divested Regulatory and Medical Writing business, which was quoted as having “generated approximately $17 million of adjusted EBITDA
in 2025 excluding unallocated overhead costs” (emphasis added), which should have been quoted as having “generated
approximately $17 million of adjusted EBITDA in 2025 including unallocated overhead costs” (emphasis added).
The 2025 adjusted EBITDA generated by the Regulatory
and Medical Writing business excluding unallocated corporate expense that will remain with the Company is approximately $23 million.
The second quarter 2026 earnings presentation contained the same misstatement
and an updated version of the presentation has been posted to the Company’s website, available at ir.certara.com under the heading
“Financials & Filings - Quarterly Results”.
The foregoing clarification has no impact on previously reported financial
results, year-over-year comparisons or the Company’s 2026 Financial Outlook.